Darbepoetin alfa (Aranesp)

A recombinant protein which stimulates ERYTHROPOIESIS used to treat ANEMIA.

Also Known As:

Aranesp; Aranest; Darbepoietin alfa; KRN 321; KRN-321; KRN321; NESP; Novel Erythropoiesis Stimulating Protein; 30-l-Asparagine-32-l-threonine-87-l-valine-88-l-asparagine-90-l-threonineerythropoietin (human)

Networked: 571 relevant articles (88 outcomes, 225 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	McMurray, John J V: 29 articles (01/2022 - 03/2005)
2.	Pfeffer, Marc A: 25 articles (04/2022 - 03/2005)
3.	Solomon, Scott D: 23 articles (01/2019 - 03/2005)
4.	Lewis, Eldrin F: 17 articles (01/2021 - 07/2009)
5.	Tomita, Dianne: 17 articles (11/2012 - 08/2002)
6.	Singh, Ajay K: 16 articles (01/2022 - 03/2005)
7.	Akizawa, Tadao: 16 articles (10/2021 - 02/2008)
8.	Eckardt, Kai-Uwe: 15 articles (09/2022 - 07/2009)
9.	Ivanovich, Peter: 13 articles (01/2019 - 03/2005)
10.	Levey, Andrew S: 13 articles (01/2019 - 03/2005)

Related Diseases

1.	Anemia 09/01/2006 - "The objective of this study was to determine if darbepoetin alfa administered at a reduced dosing frequency relative to the prior rHuEpo regimen is an effective and safe alternative for treating renal anemia in patients undergoing dialysis. " 08/01/2005 - "These results demonstrate that darbepoetin alfa is a safe and effective treatment for anemia in renal transplant recipients." 05/01/2008 - "Darbepoetin alfa has the potential to simplify the treatment of CKD anemia with many advantages, including infrequent dosing, improved patient convenience and compliance, and decreased healthcare resource utilization. " 01/01/2020 - "Finally, JR-131 stimulated erythropoiesis and improved anemia in rats similarly to darbepoetin alfa. " 01/01/2023 - "This study is to evaluate the effects of darbepoetin alfa (darbe) on neutrophil count in preterm neonates treated for anemia of prematurity. "
2.	Neoplasms (Cancer) 09/01/2009 - "We report results from a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy and safety of fixed-dose Q3W darbepoetin alfa in patients with a wide variety of tumor types who experienced CIA. " 01/01/2006 - "A subsequent dose-finding study of once-every-3-week darbepoetin alfa treatment showed that the drug was effective and well-tolerated in anaemic cancer patients and reduced the need for transfusions at all doses compared with placebo. " 08/01/2003 - "This phase 3, randomized, double-blind, placebo-controlled study was designed to evaluate the efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. " 08/01/2003 - "Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study." 10/01/2002 - "Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies."
3.	Chronic Renal Insufficiency 06/01/2007 - "Data from several randomized studies have shown that darbepoetin alfa is effective in maintaining haemoglobin levels when administered (subcutaneously, intravenously or both) every 2 weeks in dialysis patients, and every 2 weeks or monthly in patients with chronic kidney disease not yet receiving dialysis. " 06/01/2012 - "Darbepoetin alfa (DA) has been shown to be an effective treatment of anaemia in patients with chronic kidney disease (CKD) not on dialysis (NoD). " 03/01/2010 - "Multiple studies have shown that epoetin alpha (r-HuEpo) and darbepoetin alpha (NESP) are similarly effective and safe for maintaining haemoglobin levels in patients with chronic kidney disease (CKD). " 10/01/2006 - "The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis." 02/01/2019 - "Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan."
4.	Fatigue 04/01/2011 - "Darbepoetin alfa confers a consistent, but small, improvement in fatigue and overall quality of life but not in other domains. " 08/21/2002 - "Patients receiving darbepoetin alfa required fewer transfusions (27% versus 52%; mean difference = 25%; 95% confidence interval [CI] = 14% to 36%; P<.001), required fewer units of blood (0.67 versus 1.92; mean difference = 1.25, 95% CI = 0.65 to 1.84; P<.001), had more hematopoietic responses (66% versus 24%; mean difference = 42%; 95% CI = 31% to 53%; P<.001), and had better improvement in FACT-Fatigue scores (56% versus 44% overall improvement; 32% versus 19% with >or=25% improvement; mean difference = 13%; 95% CI = 2% to 23%, P =.019) than patients receiving placebo. " 11/19/2009 - "There was only a modest improvement in patient-reported fatigue in the darbepoetin alfa group as compared with the placebo group. " 04/01/2004 - "Darbepoetin alfa also improved fatigue compared with placebo in both haemoglobin categories. " 03/01/2012 - "The total standardized effect of darbepoetin alfa on fatigue outcomes corresponded to a mean change of 0.9 to 3.5 points in FACT-F scores, with one trial demonstrating changes exceeding the minimal important difference of 3 points. "
5.	Heart Failure 12/01/2008 - "Darbepoetin is, however, currently being tested in a large-scale, phase III morbidity and mortality trial, the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF) which should contribute important information of the safety and efficacy of ESAs in this syndrome. " 05/01/2006 - "Darbepoetin alfa increased haemoglobin levels in heart failure patients and improved some aspects of quality of life compared to placebo. " 03/01/2013 - "This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes. " 03/01/2013 - "Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)." 03/01/2012 - "The RED-HF study will show whether use of darbepoetin alfa in anemic patients with chronic HF will reduce the combined endpoint of death for any reason or hospitalization for heart failure."

Related Drugs and Biologics

1.	Epoetin Alfa (Epogen)
2.	Hemoglobins (Hemoglobin)
3.	Darbepoetin alfa (Aranesp)
4.	Hematinics
5.	Erythropoietin
6.	pegfilgrastim (Neulasta)
7.	vadadustat
8.	continuous erythropoietin receptor activator
9.	Intercellular Signaling Peptides and Proteins (Growth Factors)
10.	epoetin beta

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Peritoneal Dialysis
4.	Renal Dialysis (Hemodialysis)
5.	Radiotherapy